Health CanadaType I
APO-QUETIAPINE XR - May exceed the established acceptable intake limit for N-nit...
Published: January 31, 2025Recall ID: 76888Category: generalCountry: Canada
Reason for Recall / Hazard
Product quality
Product Description & Identification
Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada.
Affected Products
APO-QUETIAPINE XR
Additional Source Details
| Field | Value |
|---|---|
| N I D | 76888 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/apo-quetiapine-xr-may-exceed-established-acceptable-intake-limit-n-nitroso-desalkyl |
| Issue | Product quality |
| Title | APO-QUETIAPINE XR - May exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP). |
| Product | APO-QUETIAPINE XR |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2025-01-31 |
| Organization | Drugs and health products |
| Recall class | Type I |
| What you should do | Verify if your product is affected. Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns. Contact the recalling firm if you have any questions about the recall.Report any health product related side effects to Health Canada.Report any other health product safety complaints to Health Canada. |